Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
The FDA removed semaglutide from the drug shortage list in February 2025 and tirzepatide in December 2024
Note: Percentages are aggregated from major clinical trials (e.g., STEP, SURMOUNT) and represent the highest dose groups
Tirzepatide is a dual GIP/GLP-1 receptor agonist , meaning it activates two gut hormone receptors that help regulate appetite, digestion, and blood sugar
Resume at your normal dose on the next available day
Benefits Enhances natural pulsatile growth hormone secretion: CJC-1295 (No DAC) amplifies endogenous growth hormone release by directly stimulating the GHRH receptor pathway in the anterior pituitary
US$ 25.44
US$ 24.94
US$ 21.72
US$ 25.01
US$ 25.73
US$ 21.03
US$ 27.30
US$ 22.07
US$ 27.49
